320777-05-7
320777-05-7
Chemical Structure
GLY-230
- CAS No.: 320777-05-7
- Formula:C14H12ClNO2
- Molecular Weight:261.70
IUPAC Name: 2-(2-((3-chlorophenyl)amino)phenyl)acetic acid
InChIKey: ZTFVCZLJMNRVHT-UHFFFAOYSA-N
SMILES: OC(CC(C=CC=C1)=C1NC2=CC(Cl)=CC=C2)=O
Biological Activity: GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GLY-230 | GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kennedy L, et al. Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. Am J Nephrol. 2010;31(2):110-6. [Content Brief]
- [2]. Cohen MP, et al. Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate. Clin Exp Pharmacol Physiol. 2009 Nov;36(11):1099-103. [Content Brief]
